Columbia University

Technology Ventures

Xylyx Bio

Xylyx Bio: With an understanding that the development of better medicine begins with better disease models, Dr. Gordana Vunjak-Novakovic and Dr. John O’Neill founded Xylyx Bio to commercialize products that support cell models that provide significantly more predictive and actionable results in drug discovery. Rather than synthetic or single molecule products, Xylyx Bio’s native tissue products provide a cell environment that is more predictive of human physiology, allowing scientists to gain vital insights into the underlying mechanisms of disease, better assess which drug candidates will be safer and more effectively treat patients, and reduce risk and the associated time and money related to drug failure.

To learn more about this opportunity, contact:

Beth Kauderer
Technology Licensing Officer
beth.kauderer@columbia.edu